UK – Tecartus wins NICE recommendation for mantle cell lymphoma

The UK’s National Centre for Health and Care Excellence (NICE) has recommended Kite’s CAR-T therapy Tecartus (autologous anti-CD19 transduced CD3+ cells) for the treatment of certain adult patients with relapsed or refractory mantle cell lymphoma (MCL) on the NHS.

NICE’s technology appraisal committee has recommended Tecartus for use through the Cancer Drugs Fund (CDF) for patients in England and Wales.

The managed access agreement will allow NICE to collect more data on the therapy while patients can access the ‘cutting-edge’ cancer treatment.

NICE has asked for this further data because it found that there is not enough evidence on whether lymphoma patients receiving the CAR-T therapy can be cured.

The additional data will be collected on markers including progression-free survival, overall survival and the age of patients when treatment starts…